NCT00557973View on ClinicalTrials.gov

A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Muscle Spasticity
Interventions
DRUG

XP19986 SR1, 10 mg BID

XP19986 Sustained Release (SR) 10 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods

DRUG

XP19986 SR1, 20 mg BID

XP19986 Sustained Release (SR) 20 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods

DRUG

XP19986 SR1, 30 mg BID

XP19986 Sustained Release (SR) 30 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods

DRUG

Placebo

Placebo tablets to match active intervention, taken twice a day (BID) for approximately 26 days with titration and taper periods. Also taken during placebo washout periods.

Trial Locations (11)

Unknown

Downey

Gilroy

Pasadena

San Jose

Englewood

Miami

Atlanta

Chicago

Kansas City

Ann Arbor

Detroit

All Listed Sponsors
lead

XenoPort, Inc.

INDUSTRY

NCT00557973 - A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury | Biotech Hunter | Biotech Hunter